pakistan
Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery
Key takeaways
- The funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures and Alphabet, along with new backers MGX, Temasek and Capital G.
- “This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all diseases,” said founder and CEO Demis Hassabis.
- Isomorphic was founded in 2021 as a spin-off from Google DeepMind, an AI research lab acquired by Alphabet in 2014.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive Capital.
The funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures and Alphabet, along with new backers MGX, Temasek and Capital G.
The development comes amid a broader industry push to demonstrate practical applications of AI in the healthcare sector, including its ability to accelerate research and development along with shortening drug discovery timelines.
Article preview — originally published by ARY News. Full story at the source.
Read full story on ARY News →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from ARY News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop